06127 JOINN
- 8.690
- -0.240-2.69%
JOINN News
Joinn Laboratories (06127.HK) spent 10.3335 million yuan on January 3 to repurchase 0.6137 million A-shares.
On January 3, 2023, Gelonghui reported that Joinn Laboratories (06127.HK) announced the repurchase of 613,700 A-shares for 10.3335 million yuan, with a repurchase price of 16.35 to 17.2 yuan per share.
Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) Share Price Could Signal Some Risk
Joinn Laboratories (06127) spent 3.282 million yuan on December 31 to repurchase 0.194 million A-shares.
Joinn Laboratories (06127) announced that it will spend 3.282 million yuan to buy back ...
Joinn Laboratories (06127.HK) spent 1.704 million yuan to repurchase 0.1 million A-shares on December 30.
On December 30, Gelonghui reported that Joinn Laboratories (06127.HK) announced the repurchase of 0.1 million A-shares, costing 1.704 million yuan, on December 30, 2024, with a repurchase price of 16.88-17.11 yuan per share.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
Joinn Laboratories (06127.HK) spent 1.714 million yuan to repurchase 0.1 million shares of A-shares on December 23.
On December 23, Gelonghui reported that Joinn Laboratories (06127.HK) announced that on December 23, 2024, it spent 1.714 million yuan to repurchase 0.1 million A-shares, with a repurchase price of 17.1 to 17.18 yuan per share.
Joinn Laboratories will provide Staidson Group with comprehensive pharmaceutical R&D services covering both non-clinical and clinical trial phases.
Joinn Laboratories (06127) announced that on December 20, 2024, the company entered into a framework agreement for Staidson's research and development services for 2025, which will be effective from January 1, 2025, to December 31, 2025. The company is required to provide the Staidson Group with comprehensive pharmaceutical research and development services covering non-clinical and clinical trial phases in accordance with the 2025 Staidson research and development services framework agreement. Due to the long-term cooperation with the Staidson Group, we are able to further expand into the pharmaceutical contract research organization service market and enhance our brand reputation, the Director believes that the 2025 Staidson research and development services framework agreement is in line with the company's strategy.
JOINN Laboratories Announces Board Roles and Leadership
JOINN Laboratories Redirects Funds to Boost U.S. Operations
JOINN Laboratories Partners With Staidson for 2025 R&D Services
Joinn Laboratories (06127.HK) has entered into a research and development service agreement with Staidson for the year 2025.
On December 20, Gelonghui reported that Joinn Laboratories (06127.HK) announced that on December 20, 2024, the company entered into a 2025 research and development service framework agreement with Staidson, which will be effective from January 1, 2025, to December 31, 2025. The company is required to provide Staidson Group with comprehensive pharmaceutical research and development services covering non-clinical and clinical trial phases according to the 2025 Staidson research and development service framework agreement.
Express News | Joinn Laboratories China - Zuo Conglin Resigned as Executive Director
Joinn Laboratories (603127.SH): plans to invest no more than 8 million yuan to establish the first phase of the Peking Fund.
On December 20, Gelonghui reported that Joinn Laboratories (603127.SH) announced that the company or its designated subsidiaries intend to sign a partnership agreement (hereinafter referred to as the "Partnership Agreement") with Peking Chongde Yingsheng Investment Management Co., Ltd. (hereinafter referred to as "Chongde Yingsheng"), Peking Huizhi Fu Technology Development Co., Ltd. (hereinafter referred to as "Huizhi Fu"), and Peking Guochao Super-Group Intelligent Technology Co., Ltd. (hereinafter referred to as "Guochao Super-Group") to participate in the investment in the Northern Brain Phase I Fund (hereinafter referred to as "this Fund"). This Fund plans to focus on brain science and mainly invest in areas such as the diagnosis and treatment of a new generation of neurological diseases.
Joinn Laboratories (06127.HK) spent 1.8777 million yuan to repurchase 0.109 million A shares on December 17.
On December 17, Gelonghui reported that Joinn Laboratories (06127.HK) announced the repurchase of 0.109 million A-shares for a total cost of 1.8777 million yuan on December 17, 2024, with a repurchase price of 17.1-17.28 yuan per share.
A total scale of 30 billion! The first national-level mother fund in the foreign trade and economic field is being raised, introducing listed company LP Jinbo Bio and Joinn Laboratories.
① The Innovation and Development Guidance Fund for Service Trade is a national-level fund initiated by the Ministry of Finance, the Ministry of Commerce, and China Merchants Group, approved by the State Council, with a total scale of 30 billion yuan. ② An IR practitioner stated to the Star Daily that the second phase of the service trade fund inviting listed companies to become LPs may be a more market-oriented signal.
Joinn Laboratories (06127.HK) spent 0.885 million yuan on December 13 to repurchase 0.05 million shares.
On December 13, Gelonghui reported that Joinn Laboratories (06127.HK) announced that on December 13, 2024, the company spent 0.885 million yuan to repurchase 0.05 million shares on the Shanghai Stock Exchange, with a repurchase price of 17.7 yuan per share.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
Honkong stock market movement | CRO concept stocks collectively opened higher as the bioprotective legislation was not included in the final version of the NDAA by the U.S. Senate and House of Representatives.
CRO concept stocks opened higher collectively. As of the time of writing, wuxi bio (02269) increased by 13.03%, trading at 19.6 Hong Kong dollars; wuxi apptec (02359) rose by 11.72%, trading at 61 Hong Kong dollars; pharmaron (03759) climbed by 9.14%, trading at 16 Hong Kong dollars.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Hong Kong stocks unusual movement | CRO concept stocks expanded their gains, wuxi apptec (02359) surged 12% at one point. It is rumored that US legislators are considering making changes to the bioterrorism law.
CRO concept stocks further expanded their gains. As of the time of publication, wuxi apptec (02359) rose by 10%, trading at 55 Hong Kong dollars; pharmaron (03759) increased by 8.12%, trading at 14.64 Hong Kong dollars; wuxi bio (02269) went up by 7.02%, trading at 17.6 Hong Kong dollars.
No Data
